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Androgen-independent prostate carcinoma (AICP) is one of the tumors that continue to respond poorly to
chemotherapy. Recently, protocols based on the use of docetaxel have significantly improved survival for
patients in this disease. In other types of neoplastic disease, combined therapy with taxanes and anthracycline
derivatives has been shown to produce additive effects in terms of growth inhibition, and superior tolerability
when associated with weekly administration schedules. These findings prompted us to examine the tolerabil-
ity and efficacy of weekly treatment of AICP with docetaxel (DOX) plus epirubicin (EPI). We enrolled 35
chemotherapy-naive men with AICP (mean age 72 years, range 68–77) and normal hepatic, renal, and
cardiac function. The chemotherapy protocol provided for the IV administration of DOX (30 mg/m2) and
EPI (30 mg/m2) on days 1, 8, and 15 every 28 days. Treatment was continued for 6 months or until disease
progression and/or unacceptable toxicity was observed. Serum levels of prostate-specific antigen (PSA) were
monitored in all patients, and reductions from baseline values of >50% were considered indicative of positive
responses to treatment. Thirty-four patients were included in the analysis of toxicity, and objective responses
to treatment were assessed in the 28 patients with measurable lesions. Nineteen patients (56%) experienced
PSA reductions of >50% that persisted for more than 4 weeks. The response to therapy was classified as
complete in 1 of the 28 patients (4%) with measurable disease (at the lymph node level). Thirteen others
(13/28, 46%) had partial responses, in nine (32%) the disease remained unchanged, and progression was
observed in the remaining five (18%); overall response rate was 50% (CR + PR). Of the 27 patients with
pain at the time of enrollment, 16 (59%) experienced pain reduction during treatment. The median time to
disease progression was 11.7 months (95% CI: 7.7–15.7) while the median survival time was 18.7 months
(95% CI: 12.3–25.1). During the study, four patients developed grade 3 anemia and leukopenia, which was
reversible in all cases. Lower grades of asthenia, nausea, vomiting, diarrhea, and peripheral edema were also
observed. There were no cases of cardiotoxic effects. Alopecia was frequent but reversible in all cases. The
results of this preliminary study indicate that the combined administration of DOX and EPI for treatment of
AIPC is effective and well tolerated. The weekly administration of the drug combination appears to be a
promising approach to the treatment of these tumors.
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INTRODUCTION selection model proposed by Isaac and Coffey (6), in
which disease progression mainly involves cell popula-
tions that are refractory to hormone therapy, a character-Carcinoma of the prostate is the major cause of mor-
bidity and mortality among elderly men in Western istic that is often associated with increased expression of
the oncogene BCL-2. Overexpression of this oncogenecountries (1), and it has increased by 3% per year over
the past decade (2). This is a hormone-dependent tumor, protects the tumor cells from the apoptotic effects of
most chemotherapy agents (7,8). This probably explainsand androgen blockade is currently the first and the most
effective treatment. Although most patients respond pos- why chemotherapy for androgen-independent prostate
cancer (AIPC) has thus far produced only transient re-itively to this type of treatment, the duration of the re-
sponse is hard to predict. Data from randomized trials sponses and/or marginal benefits in terms of symptom
palliation (9,10).and studies of patients with advanced disease indicate
that the median time to progression ranges from 12 to Recently, however, interest in cytotoxic chemother-
apy for prostate cancer has been renewed by the results18 months, and median survival varies from 24 to 36
months (3–5). These data are consistent with the clonal obtained in clinical trials with the combined use of estra-
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mustine and docetaxel (11–14). These observations DOX was diluted in 500 cc of a saline solution and
administered by IV infusion over 2 h, followed by anprompted us to consider three aspects of the problem.
First, the most promising chemotherapeutic agents avail- IV bolus of EPI diluted in 100 cc of saline solution.
Premedication for DOX included dexamethasone (8 mg)able today for treatment of AIPC are those that act on
the microtubules, docetaxel (DOX) in particular. Sec- administered by intramuscular injection the evening be-
fore the treatment day and again at the time of treatment.ond, both DOX and anthracycline derivatives like epiru-
bicin (EPI) can provoke apoptosis in prostate carcinoma Ondansetron (8 mg) was administered IV at the begin-
ning of each cycle to control nausea and vomiting.cells that overexpress the BCL-2 oncogene (15,16).
Third, experimental and clinical studies have shown In the presence of grade 3 (or higher) hematological
toxicity, the doses of DOX and EPI were reduced bythat, in other types of neoplastic disease, the use of tax-
anes with anthracycline derivatives produces additive ef- 25% or treatment was postponed until complete recov-
ery had occurred.fects against the neoplastic cell clone (17,18). These
considerations and the fact the AIPC patients are gener-
ally quite elderly led us to evaluate both the tolerability Criteria Used to Assess Toxicity and Response
to Treatmentand clinical efficacy of a schedule with DOX plus EPI
administered on a weekly basis, which allowed for better
Vital signs, adverse effects, performance-status scores,
control of the comorbidity caused by the toxic effects of
and complete blood counts were recorded weekly for
the drugs being used.
each patient. Clinical evaluations, including measure-
ment of PSA and instrumental studies of target lesions,PATIENTS AND METHODS
were performed every 4 weeks. Pain responses were
Patients evaluated with the orally administered McGill-Melzac
questionnaire (19), in which pain is rated according to aEligible patients had histologically confirmed adeno-
5-point scale (0 = no pain, 1 = mild, 2 = discomforting,carcinoma of the prostate with advanced stage and/or
3 = distressing, 4 = horrible, 5 = excruciating).metastatic disease that had showed signs of progression
The criteria used in assessing the efficacy of treat-during standard hormonal therapy. Additional inclusion
ment were: reduction of PSA levels by at least 50% thatcriteria were: <80 years old; informed consent; Eastern
persisted for at least 4 weeks; pain reduction of twoCooperative Oncology Group (ECOG) score ≤2; absence
points or more on the McGill Melzack questionnaire.of brain metastases; normal cardiac, hepatic, renal, and
We also assessed the effect of treatment on measur-bone marrow function; nNo prior chemotherapy with cy-
able lesions in accordance with the WHO criteria fortotoxic drugs.
evaluation of the response to treatment of solid tumors.Disease progression was defined by the presence of
at least one of the following: an increase of 25% or more
Statistical Methodsin serum levels of PSA in two consecutive measure-
ments obtained at least 1 week apart; aAn increase of The study was a nonrandomized, phase II study. The
25% or more in the size of metastatic lesions or the ap- primary end point included the evaluation of the regi-
pearance of new lesions; appearance of new bone le- men-related toxicities and objective responses, and after
sions documented by bone scan. time to disease progression (TTP) and overall survival
Androgen blockade achieved with LH-RH analogs (OS). The sample size was calculated on the assumption
was maintained in all patients.At the time of enrollment that a percentage of objective response variables be-
and prior to the initiation of treatment, each patient had tween 20% and 40% could be detected. According to the
a thorough physical examination, and standard blood optional Simon two-step design, if a minimum objective
chemistry parameters were measured along with serum response rate >20% was observed in the first 15 patients,
levels of testosterone and PSA. The patient also had a an additional 15 patients should be enrolled, and if >12
total-body bone scan, radiologic studies aimed at locat- responses were observed in 30 patients (40%), the regi-
ing the cause of pain, and, when indicated, computed men was considered active to be submitted for further
tomographic scans of the chest and abdomen. evaluation (20). Descriptive statistics was reported as
proportions and medians. TTP was defined as the inter-
Treatment Regimen val between initial treatment and the time of disease pro-
gression or death. Survival time was calculated from theDOX (30 mg/m2) and EPI (30 mg/m2) were adminis-
tered on days 1, 8, and 15 every 28 days. The treatment date of treatment initiation until the date of the last fol-
low-up evaluation or death. TTP and OS were analyzedwas repeated for 6 months or until evidence of disease
progression, patient refusal, or unacceptable adverse re- according to the Kaplan-Meier method (21). The confi-
dence intervals (CIs) for response rates, TTP, and OSactions.
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were calculated using methods for exact binominal con- proved during treatment in 16/34 patients (47%). Specif-
ically, pain improved in 16 of the 27 (59%), remainedfidence interval (22). Survivors were censored on the
date they were last known to be alive. stable in 15%, and worsened in 26% (Table 2).
A total of 184 cycles of treatment were administered
during the trial, with a mean of 5.4 cycles per patientRESULTS
(3–8 cycles). In three cases (9%), a 25% dose reduction
The characteristics of the 35 patients enrolled in the
was necessary because the patient developed grade 3 he-
trial are reported in Table 1. One patient withdrew from
matological toxicity; in two others (6%) the treatment
the study after the second week without completing the
was simply postponed for 7 days. Two patients devel-
first cycle of treatment. Of the 34 patients who com-
oped grade 3 anemia, and three others experienced non-
pleted the treatment as planned, 28 had measurable le-
febrile leukopenia. Table 3 shows the adverse effects
sions. One patient achieved a complete response (CR
observed during the trial.
rate = 4%), and 13/28 had partial responses (PR rate =
46%). In nine patients, the disease remained stable (SD
DISCUSSIONrate = 32%), and disease progression was observed in
the other five (PD = 18%). Figures 1 and 2 report the
Androgen-independent prostate cancer (AIPC) is one
curve of median time to progression, which was 11.7
of the unresolved problems in the field of treatment for
months (range 6.1–20.1, 95% CI 7.7–15.7), and the me-
solid tumors. Most chemotherapeutic agents have dis-
dian survival time, which was 18.7 months (range
played only marginal activity against these tumors, but
8.1–36+, 95% CI 12.3–25.1).
in recent years promising results have emerged from
Reductions of >50% in serum PSA levels were ob-
studies of taxanes and other chemotherapy agents that
served in 19/34 patients (56%), and the mean duration
act on the microtubules. These agents are the first drugs
of this response was 5.4 months (range 2.4–7.8, 95% CI
that seem to be able to increase survival in patients with
3.6–7.2), and reductions of <50% were observed in nine
AIPC (23,24). Anthracycline derivatives have also dis-
(26%) others. On the whole, performance status im-
played some degree of efficacy in the treatment of ad-
vanced prostate cancer (25), and clinical trials have re-
vealed additive effects when these drugs are used withTable 1. Clinical Characteristics of the Patients
taxanes in the treatment of other types of tumors (26,27).
No. Therefore, in the present study we evaluated the efficacy
Patients and safety of weekly administration of DOX + EPI for
Characteristics (%) treatment of advanced AIPC and control of the pain that
often accompanies this disease.
Age (years; median 72, range 68–77) 35
The DOX + EPI regimen was associated with anECOG performance status
overall response rate of 50% (1 CR + 13 PR). In nine0 11 (32)
patients, the disease remained stable, and progression1 19 (54)
was observed in the remaining five (18%). A reduction2 5 (14)
of >50% in serum PSA levels occurred in 19/34 patientsMain site of metastases
Bone 20 (57) (57%). Moreover, weekly administration of the two
Soft tissue and/or lymph nodes 8 (23) drugs was well tolerated. Ninety-one percent of the pa-
Lung 4 (12) tients completed the six cycles of treatment provided for
Liver 3 (8) in the study protocol, and none experienced adverse
Hormone therapy (LHRH agonists + events serious enough to warrant discontinuation of
androgen blockers)* 35 (100) treatment. The most severe adverse events were grade 3
Baseline serum PSA levels (ng/ml)
anemia and leukopenia, which occurred in four patientsMedian 172
(12%). All of these episodes resolved completely with-Range 7–1700
out hospitalization. There were no cases of thromboem-Baseline pain intensity scores
bolic complications, signs of cardiotoxicity, or astheniaGrade 0 8 (23)
>grade 2. This rate is higher than those reported in pa-Grade 1 4 (12)
Grate 2 12 (33) tients treated with other chemotherapy drugs, especially
Grate 3 8 (23) estramustine (9,11–14), which is also associated with
Grade 4 2 (6) poorly tolerated gastrointestinal side effects.
Grade 5 1 (3) Of the 28 patients with measurable lesions, one (4%)
had a complete response to treatment, and 13 others*Hormone treatment begun prior to study enrollment was continued
during the study. (46%) had partial responses. The overall objective re-
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Figure 1. Kaplan-Meier estimates of time to progression among patients with prostate cancer treated with the docetaxel and
epirubicin weekly regimen.
Figure 2. Kaplan-Meier estimates of overall survival among patients with prostate cancer treated
with the docetaxel and epirubicin weekly regimen.
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Table 2. Results of Patients Who Could Be Evaluated AIPC and provide rapid and effective control of pain
with provoking uncontrollable or irreversible toxicity.
Results No. (%) These preliminary findings confirm the results of other
studies, which showed that DOX therapy for AIPC isBiological response 34 (100)
well tolerated and associated with good objective re-Reduction in serum PSA >50% 19 (56)
sponse rates (25,26). Most AIPC patients are elderlyReduction in serum PSA <50% 9 (26)
Response to treatment 28 (100) men with multiple concomitant diseases, and their bone
Complete response 1 (4) marrow responses are often reduced. For this reason, we
Partial response 13 (46) feel that the control of symptoms and good tolerability
Disease stabilization 9 (32) should be the primary objectives of treatment in AIPC
Disease progression 5 (18) patients. In this context, better results might be achieved
Pain† 27 (100) by subjecting responding patients to intermittent treat-
Improved 16 (59)
ment, as soon as disease progression occurs. The mainUnchanged 4 (15)
limitation of our study was the number of enrolled pa-Worsened 7 (26)
tients. Because the number of patients was so small, no
*Patients with measurable lesions: 28/34. conclusive answer can be drawn. Our future efforts will
†Patients with pain at enrollment: 27/34. focus on randomized trials evaluating this DOX + EPI
regimen with DOX alone or DOX in other combina-
tions.
sponse rate was thus 50% (1 CR + 13 PR). In nine pa-
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